mediate behaviour with serum concentration of 28.8±16.4 ng/ml and endometrium concentration of 2047±1809 ng/g (100-fold increase). Serum and tissue concentrations of all compounds were not linearly correlated with treatment duration. No significant relationship was found between hysteroscopic features and compound concentrations. A highly significant ($P < 0.01$) difference in tamoxifen tissue concentration was found between atrophic and hyperplastic endometrium at biopsy.

5. Conclusions

Congruent with previous studies on rats, tamoxifen and its metabolites are actively concentrated in human endometrial tissue as in other human tissue, but it is unlikely that the avidity of these metabolites for oestrogen receptor could totally explain this active concentration. Increased receptor distribution in hyperplastic endometrium could, on the other hand, account for increased tamoxifen concentrations, and this should be further investigated.

Abstract: P10

Downregulation of oestrogen receptor in advanced breast cancer after lipofection with wild-type (w-t) insulin growth factor binding protein IGFBP-2 cDNA plasmid

J. Giannios *, N. Alexandropoulos, A. Koratzis, M. Yiannios

Ippokration Hospital, Athens, Greece

1. Introduction

Development of anti-oestrogen resistance and oestrogen independence in human breast cancer is associated with a reduction in the level of secretion of IGFBP-2 (IGF-1 binding protein), which is an important modulator of IGF-1 action. This may be caused due to mutations in IGFBP-2.

2. Objective

Thus, we believed that and studied whether upregulation of IGFBP-2 would enhance the level of IGFBP-2 synthesis and circumvent anti-oestrogen resistance to breast carcinoma cells.

3. Materials, methods and results

We obtained tamoxifen-resistant breast carcinoma cells from a patient by fine-needle biopsy. Immunocytochemistry (ICC) and polymerase chain reaction (PCR) analysis exhibited inactivated IGFBP-2 due to mutations. Then, we encapsulated wild-type (w-t) IGFBP-2 cDNA plasmid in DRV liposomes and incubated these with breast tumour cells at 37°C for 6 h. ICC and PCR analysis exhibited normal expression of IGFBP-2. Furthermore, electron microscopy exhibited induction of PCD in treated tumour cells. Subsequently, these tumour cells were incubated with tamoxifen-molecules for 4 h at 37°C. Biochemical assays such as DNA synthesis (BrdU) metabolic activity (MTT), clonogenicity and trypan blue viability showed much lower percentage values compared with controls.

4. Conclusion

Gene replacement using liposomal w-t IGFBP-2 cDNA circumvented tamoxifen resistance in advanced breast carcinoma cells.

* Corresponding author.

0959-8049/00/$ - see front matter © 2000 Published by Elsevier Science Ltd.
PII: S0959-8049(00)00256-2